AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23434737 — intervention group
Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations (different preservatives)
Number of subjects: 150
Study 23434737 — intervention group
Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations (different volumes: 0.5 or 1 ml)
Number of subjects: 150
Study 23434737 — intervention group
Group type: EXPERIMENTAL
Intervention: gD2-AS04 vaccine formulations
Number of subjects: 150
Study 20350333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 500 mg twice daily
Number of subjects: 80
Study 20350333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19122492 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening program for the lower back (lumbar stabilization exercises and education on pain management) for 8 weeks, 3 days a week
Number of subjects: 30
Study 19122492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 30
Study 16624552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg daily)
Number of subjects: 377
Study 16624552 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (general treatment)
Number of subjects: 377
Study 14642458 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based morphometry (VBM)
Number of subjects: 10
Study 10962114 — intervention group
Group type: EXPERIMENTAL
Intervention: Batista procedure
Number of subjects: 0
Study 9201637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy and exercises
Number of subjects: 45
Study 9201637 — intervention group
Group type: COMPARATOR
Intervention: Exercises alone
Number of subjects: 45
Study 1532316 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg slow release oral isradipine
Number of subjects: 10
Study 1532316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2948162 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg
Number of subjects: 189
Study 2948162 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 100 mg
Number of subjects: 189
Study 2948162 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 189
Study 2948162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 30160335 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation (n = 5)
Number of subjects: 10
Study 30160335 — intervention group
Group type: COMPARATOR
Intervention: Sham (n = 5)
Number of subjects: 10
Study 30160335 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal nerve block (used by 80% of subjects)
Number of subjects: 10
Study 29259382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (7.5 mg)
Number of subjects: 56
Study 29259382 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 mg)
Number of subjects: 56
Study 29259382 — intervention group
Group type: COMPARATOR
Intervention: Comparison of tolvaptan vs furosemide
Number of subjects: 56
Study 25850814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-β-glucan tortillas
Number of subjects: 12
Study 25850814 — intervention group
Group type: EXPERIMENTAL
Intervention: High insoluble fibre tortillas
Number of subjects: 12
Study 25850814 — intervention group
Group type: COMPARATOR
Intervention: Low-β-glucan tortillas
Number of subjects: 12
Study 25850814 — intervention group
Group type: COMPARATOR
Intervention: Low insoluble fibre tortillas
Number of subjects: 12
Study 23293333 — intervention group
Group type: EXPERIMENTAL
Intervention: CoA 200 U/d (group B)
Number of subjects: 244
Study 23293333 — intervention group
Group type: EXPERIMENTAL
Intervention: CoA 400 U/d (group C)
Number of subjects: 244
Study 23293333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 244
Study 20552330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene-rich tomato juice
Number of subjects: 60
Study 20552330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene capsules
Number of subjects: 60
Study 20552330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation (combined juice and capsules)
Number of subjects: 60
Study 20552330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19567023 — intervention group
Group type: EXPERIMENTAL
Intervention: Chai Shao Liu Jun Tang in combination with Lamivudine
Number of subjects: 405
Study 19567023 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 405
Study 17878255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in women (12.5 ng/ml)
Number of subjects: 1862
Study 17878255 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in women (0.75 mg/liter)
Number of subjects: 1862
Study 17878255 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CRP and leptin in women
Number of subjects: 1862
Study 17878255 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CRP and leptin in men
Number of subjects: 1862
Study 17878255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin as a determinant of CRP in men
Number of subjects: 1862
Study 17878255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin as a determinant of CRP in women
Number of subjects: 1862
Study 17878255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization test for CRP as a causal agent for leptin
Number of subjects: 1862
Study 15268895 — intervention group
Group type: EXPERIMENTAL
Intervention: Low to moderate intensity exercise
Number of subjects: 0
Study 15268895 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 0
Study 12402413 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial echocardiograms and obstetric sonograms performed at least every 2 weeks starting from 16 weeks gestation in anti-Ro/SSA positive pregnant women
Number of subjects: 0
Study 12402413 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibodies anti-Ro/SSA and anti-La/SSB
Number of subjects: 0
Study 12402413 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term outcomes for mothers and affected children
Number of subjects: 0
Study 10682131 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatments
Number of subjects: 27
Study 10682131 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 27
Study 8272312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K and phenobarbital
Number of subjects: 0
Study 8272312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2456174 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost at a dose of 2 ng/kg/min for 6 hours daily for 6 days
Number of subjects: 17
Study 2456174 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost at a dose of 1 ng/kg/min for 6 hours daily for 6 days
Number of subjects: 17
Study 2456174 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 17
Study 30855096 — intervention group
Group type: EXPERIMENTAL
Intervention: I-CXL
Number of subjects: 60
Study 30855096 — intervention group
Group type: COMPARATOR
Intervention: S-CXL
Number of subjects: 60
Study 30855096 — intervention group
Group type: COMPARATOR
Intervention: I-SCXL
Number of subjects: 60
Study 29017162 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer without food
Number of subjects: 112
Study 29017162 — intervention group
Group type: COMPARATOR
Intervention: Patiromer with food
Number of subjects: 112
Study 24973862 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg omega‐3 fatty acid supplements (n = 28)
Number of subjects: 56
Study 24973862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 28)
Number of subjects: 56
Study 23921301 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cangrelor
Number of subjects: 67
Study 23921301 — intervention group
Group type: EXPERIMENTAL
Intervention: Supratherapeutic cangrelor
Number of subjects: 67
Study 23921301 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (positive control)
Number of subjects: 67
Study 23921301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 20868638 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb-761, 240 mg/d
Number of subjects: 157
Study 20868638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 19246729 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir 1250 mg every 12 hours on days 1-4
Number of subjects: 68
Study 19246729 — intervention group
Group type: EXPERIMENTAL
Intervention: nelfinavir 1250 mg every 12 hours on days 1-3 plus 3125 mg on day 4
Number of subjects: 68
Study 19246729 — intervention group
Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg every 24 hours on days 1-4
Number of subjects: 68
Study 19246729 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 68
Study 16618915 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (500 mg daily for 3 days)
Number of subjects: 105
Study 16618915 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg daily for 5 days)
Number of subjects: 105
Study 15585764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine intake of 5 mg.kg(‐1).d(‐1)
Number of subjects: 21
Study 15585764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystine intake of 12 mg.kg(‐1).d(‐1)
Number of subjects: 21
Study 15585764 — intervention group
Group type: COMPARATOR
Intervention: 0 mg cystine intake (previously estimated)
Number of subjects: 21
Study 11384708 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed subjects (BDI score >14)
Number of subjects: 155
Study 11384708 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed subjects (BDI score ≤14)
Number of subjects: 155
Study 11384708 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 155
Study 9480466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose methotrexate (7.5-15 mg weekly)
Number of subjects: 96
Study 8492409 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A (intermediate dose cytosine arabinoside (Ara‐C), cyclophosphamide (CPM) plus 6MP)
Number of subjects: 188
Study 8492409 — intervention group
Group type: COMPARATOR
Intervention: Regimen B (high-dose Ara‐C plus CPM)
Number of subjects: 188
Study 8492409 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A
Number of subjects: 188
Study 8492409 — intervention group
Group type: COMPARATOR
Intervention: Regimen B
Number of subjects: 188
Study 8492409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with initial leukocyte count > or = 10 x 10(4)/microliters
Number of subjects: 188
Study 8492409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with leukocyte count < 10 x 10(4)/microliter
Number of subjects: 188
Study 3284399 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw untreated cow milk
Number of subjects: 5
Study 3284399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized cow milk
Number of subjects: 5
Study 3284399 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogenized and pasteurized cow milk
Number of subjects: 5
Study 3284399 — intervention group
Group type: COMPARATOR
Intervention: Nutramigen (placebo)
Number of subjects: 5
Study 3284399 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests with raw cow milk protein extract
Number of subjects: 5
Study 3284399 — intervention group
Group type: COMPARATOR
Intervention: Nutramigen (skin prick test)
Number of subjects: 5
Study 31818531 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of refined cold-pressed flaxseed oil providing 4.7 g ALA (n = 29)
Number of subjects: 59
Study 31818531 — intervention group
Group type: COMPARATOR
Intervention: 10 g of high-oleic sunflower oil (control) (n = 30)
Number of subjects: 59
Study 29019418 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus daily motivational interviewing-based text messages
Number of subjects: 101
Study 29019418 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 101
Study 28961714 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole 300 mg twice daily on day 1, followed by 300 mg once daily for 4-28 days, then oral posaconazole 400 mg twice daily or 200 mg three times daily for 28 days.
Number of subjects: 237
Study 26290323 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with concentrated blood and bone marrow aspirate (cB + cBMA)
Number of subjects: 50
Study 26290323 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment without cB + cBMA (sham treatment)
Number of subjects: 50
Study 23406601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone furoate (FF) and intraocular placebo (PL)
Number of subjects: 0
Study 23406601 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (PL) and intraocular olopatadine (OLO)
Number of subjects: 0
Study 23406601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone furoate (FF) and intraocular olopatadine (OLO)
Number of subjects: 0
Study 23406601 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo (PL) and intraocular placebo (PL)
Number of subjects: 0
Study 23406601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone furoate (FF)
Number of subjects: 0
Study 20464787 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 80
Study 20464787 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 80
Study 18001177 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drugs (ATDs) therapy in Graves' disease
Number of subjects: 57
Study 18001177 — intervention group
Group type: COMPARATOR
Intervention: Antithyroid drugs (ATDs) therapy in painless thyroiditis
Number of subjects: 57
Study 17110267 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic cap splint type expansion appliances covering all dentition except the incisors and canine on the shifted side.
Number of subjects: 32
Study 17110267 — intervention group
Group type: COMPARATOR
Intervention: Acrylic cap splint type expansion appliances covering only the posterior teeth, from the first premolars on both sides.
Number of subjects: 32
Study 15256294 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (30-min massages three times per week for 5 weeks)
Number of subjects: 34
Study 15256294 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 34
Study 11399342 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 65
Study 11399342 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN)
Number of subjects: 65
Study 11399342 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 65
Study 9416722 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg (three times the ED95)
Number of subjects: 78
Study 9416722 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine 2 mg/kg
Number of subjects: 78
Study 9416722 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.8 mg/kg
Number of subjects: 78
Study 9416722 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 78
Study 8236504 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus NTX (100 mg every other day)
Number of subjects: 21
Study 8236504 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 21
Study 3828273 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Number of subjects: 0
Study 30326548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage of an ALDH2 rs671 A allele
Number of subjects: 4536
Study 30326548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage of an A allele in males
Number of subjects: 4536
Study 30326548 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriage of an A allele in moderate drinkers
Number of subjects: 4536
Study 30326548 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing alcohol consumption by 1.7-fold
Number of subjects: 4536
Study 30326548 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated alcohol intake
Number of subjects: 4536
Study 30326548 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 4536
Study 30326548 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake in females
Number of subjects: 4536
Study 29166200 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction
Number of subjects: 38
Study 29166200 — intervention group
Group type: COMPARATOR
Intervention: Control (no audiovisual distraction)
Number of subjects: 38
Study 26687126 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-visit treatment
Number of subjects: 220
Study 26687126 — intervention group
Group type: COMPARATOR
Intervention: Multiple-visit treatment
Number of subjects: 220
Study 23657296 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year diet and physical activity intervention with sodium restriction
Number of subjects: 285
Study 23657296 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year diet and physical activity intervention without sodium restriction
Number of subjects: 285
Study 23657296 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup with metabolic syndrome (n=98)
Number of subjects: 285
Study 21290248 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic cyclophosphamide (CYC) 900 or 1,000 mg/m²
Number of subjects: 15
Study 21290248 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic cyclophosphamide (CYC)
Number of subjects: 15
Study 19717250 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management with clinic-delivered, abstinence-based incentive program and weekly behavioral parent training sessions
Number of subjects: 69
Study 19717250 — intervention group
Group type: COMPARATOR
Intervention: Attendance-based incentive program and weekly psychoeducational parent sessions (Control)
Number of subjects: 69
Study 19717250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (MET/CBT and drug-testing program)
Number of subjects: 69
Study 19717250 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative parenting (predictor)
Number of subjects: 69
Study 17704421 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus surgery (preoperative cisplatin plus fluorouracil)
Number of subjects: 443
Study 17704421 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 443
Study 17704421 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy after R1 resection
Number of subjects: 443
Study 17704421 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 443
Study 17704421 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective tumor regression after preoperative chemotherapy
Number of subjects: 443
Study 14715820 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital irradiation
Number of subjects: 88
Study 14715820 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 88
Study 11676944 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis in grade II group
Number of subjects: 894
Study 11676944 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty in grade II group
Number of subjects: 894
Study 11676944 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis in grade III group
Number of subjects: 894
Study 11676944 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty in grade III group
Number of subjects: 894
Study 11676944 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 894
Study 11676944 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 894
Study 9174871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Number of subjects: 145
Study 9174871 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticojejunostomy
Number of subjects: 145
Study 9174871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study 7951683 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form of the CAMDEX interview
Number of subjects: 134
Study 7951683 — intervention group
Group type: COMPARATOR
Intervention: Full form of the CAMDEX interview
Number of subjects: 134
Study 2442415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pentosanpolysulfate (200 mg twice daily)
Number of subjects: 115
Study 2442415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 31937532 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning warfarin ingestion
Number of subjects: 217
Study 31937532 — intervention group
Group type: COMPARATOR
Intervention: Evening warfarin ingestion
Number of subjects: 217
Study 31937532 — intervention group
Group type: COMPARATOR
Intervention: Comparison of morning vs evening
Number of subjects: 217
Study 31937532 — intervention group
Group type: COMPARATOR
Intervention: Comparison of percent change in proportion of time outside therapeutic INR range
Number of subjects: 217
Study 31037289 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg intravitreous injection, n = 226)
Number of subjects: 702
Study 31037289 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation (n = 240)
Number of subjects: 702
Study 31037289 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation (n = 236)
Number of subjects: 702
Study 31037289 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept (for eyes in laser photocoagulation or observation groups with decreased visual acuity)
Number of subjects: 702
Study 31037289 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (Antiplatelet Trialists' Collaboration)
Number of subjects: 702
Study 27764527 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentor intervention
Number of subjects: 0
Study 26703491 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof Restor SN6AD1 multifocal IOL
Number of subjects: 39
Study 26703491 — intervention group
Group type: COMPARATOR
Intervention: Acrysof IQ monofocal IOL
Number of subjects: 39
Study 23575197 — intervention group
Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) treatment
Number of subjects: 1797
Study 21751942 — intervention group
Group type: EXPERIMENTAL
Intervention: THI-12 total score
Number of subjects: 618
Study 21751942 — intervention group
Group type: EXPERIMENTAL
Intervention: THI-12 three-factorial structure
Number of subjects: 618